Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa. The SHARPS randomized clinical trial.
Bechara FG, Podda M, Prens EP, Horvath B, Giamarellos-Bourboulis EJ, Alavi A et al.
JAMA Surg 2021; 156: 1001-1009.
The effect of perioperative adalimumab continued for ten weeks after radical surgery (wide excision followed by secondary intention healing) was examined in this study that included 206 patients. A good clinical response was more common with adalimumab therapy: 48 versus 34 per cent, P=0.049.
Comment: Some possible hope for patients with a difficult disease to manage.
1 January 2022Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.